Sleep Apnea Relief in a Pill: Apnimed Drug’s Phase 3 Data Set Stage for FDA Submission

MedCity News May 19, 2025
Frank Vinluan

Apnimed’s obstructive sleep apnea drug reduced breathing interruptions in a Phase 3 clinical trial. The once-nightly pill, which is based on research from Brigham and Women’s Hospital, activates muscles that keep the upper airway open during sleep.

Standard treatment for breathing problems caused by obstructive sleep apnea is a medical device. But many people find it uncomfortable to wear the mask that comes with a continuous positive airway pressure (CPAP) machine. Apnimed’s experimental drug could provide an easier alternative, and this pill now has results from a pivotal study the startup says support plans for an FDA submission. It could end up challenging a big pharmaceutical giant.

Apnimed’s approach to obstructive sleep apnea (OSA) is to target muscles you probably...

Today's Sponsors

Today's Sponsor